Japanese and Mid-Sized European Biotech Licensings
Executive SummaryAlliance activity over the last few years suggests that Japanese companies are more willing to take a chance on less proven, earlier-stage technology than mid-sized European companies.
You may also be interested in...
Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.
A PFS benefit and favorable tolerability profile associated with AstraZeneca’s BTK inhibitor acalabrutinib used first-line in CLL, when given alone or combined with obinutuzumab, may serve it well against entrenched competitors and BTK inhibitors in clinical development.